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Abstract
RASopathies are a group of genetic disorders that are caused by genes that affect the
canonical Ras/mitogen-activated protein kinase (MAPK) signaling pathway. Despite
tremendous progress in understanding the molecular consequences of these genetic
anomalies, little movement has been made in translating these findings to the clinic.
This year, the seventh International RASopathies Symposium focused on expanding
the research knowledge that we have gained over the years to enhance new discoveries in the field, ones that we hope can lead to effective therapeutic treatments.
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Indeed, for the first time, research efforts are finally being translated to the clinic,
with compassionate use of Ras/MAPK pathway inhibitors for the treatment of
RASopathies. This biannual meeting, organized by the RASopathies Network, brought
together basic scientists, clinicians, clinician scientists, patients, advocates, and their
families, as well as representatives from pharmaceutical companies and the National
Institutes of Health. A history of RASopathy gene discovery, identification of new disease genes, and the latest research, both at the bench and in the clinic, were
discussed.
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disorder she called “Noonan Syndrome,” a syndrome characterized by

I N T RO DU CT I O N

The RASopathies are a group of syndromic disorders caused by

valvular pulmonary stenosis, short stature, hypertelorism, and intellec-

germline mutations in genes found along the canonical Ras/mitogen-

tual disability. In 1994, after identifying a multigenerational family

activated protein kinase (Ras/MAPK) pathway, a signaling pathway

with NS, van der Burgt et al. (1994) became the first to map the loca-

critical for cellular homeostasis, cell differentiation, proliferation, and

tion of the causal mutation of the disorder to a locus in the 5–cM

survival (Tidyman & Rauen, 2016). Although individually rare, collec-

region of chromosome 12, 12q24.1. In 2000, Dr. Tartaglia began a

tively, the RASopathies comprise one of the largest families of con-

postdoctoral fellowship with Dr. Gelb, and together, in collaboration

genital disorders worldwide. Germline pathogenic variants result in

with Raju Kucherlapati, PhD, at Albert Einstein College of Medicine,

similar yet distinct syndromes, which include Noonan syndrome (NS),

Ineke van der Burgt, MD's group from the Netherlands, and Professor

Noonan syndrome with multiple lentigines (NSMLs), Costello syn-

Michael Patton's group at St. George's, London, the group identified

drome (CS), cardiofaciocutaneus syndrome (CFCS), neurofibromatosis

the NS gene. Indeed, after the successful sequencing of chromosome

type 1 (NF1), and other clinically related diseases, for example, Legius

12 as part of the Human Genome Project, it took these investigators

syndrome, Mazzanti syndrome (NS with loose anagen hair [NSLAH]),

only 1 h to identify PTPN11 as the NS-causing candidate gene

and CBL-related and MAPK1-related disorders. The phenotypic char-

(Tartaglia et al., 2001).

acteristics of the RASopathies can be severe and/or life-threatening;

In partnership with Charlotte Niemeyer, PhD, Drs. Tartaglia and

they include facial abnormalities, short stature, cardiac structural and

Gelb showed that somatic changes in PTPN11 are causal to the major-

functional defects, hematopoietic defects, skeletal malformations, and

ity of cases of juvenile myelomonocytic leukemia (JMML) and are also

certain types of cancer. These may be present at birth or develop

found in a minority of cases of B-cell lineage acute lymphocytic leuke-

throughout a patient's life. Historically, effective and targeted treat-

mia (ALL), acute myeloid leukemia (AML), and myelodysplastic syn-

ments for RASopathies have remained elusive, and patients are often

drome (Tartaglia, 2004; Tartaglia et al., 2003). These findings

left with limited or no options for treatment. Therefore, there is a criti-

established SHP2 as the first known phosphatase to act as an

cal need to move forward on this important area of research and the

oncoprotein when mutated. The specific residues involved and the

promise of finding effective treatments for RASopathies. It is clear

types of substitutions that occurred in these NS-associated oncogenic

that having a better understanding of the molecular targets for these

somatic variants of SHP2 differed from those that were NS-

disorders paves the way for generating more effective, more targeted,

associated germline variants. In fact, somatic variants associated with

and

patients with

leukemias had higher catalytic activity of SHP2, a more pronounced

RASopathies. The seventh International RASopathies Symposium,

hypersensitivity to cytokines and growth factors, and a higher trans-

held virtually on July 23–25, 2021, aimed to expand our understand-

formation potency than those that were non-leukemia generating NS

ing of the newest research in the field, to enhance our knowledge of

mutations (Keilhack et al., 2005). Moreover, these mutations were

potential new molecular and genetic discoveries, and to help us iden-

found to be embryonic lethal.

more

personalized

therapies

for

treating

tify new therapeutic targets for treating these disorders. In this

Subsequent studies revealed that PTPN11 variants are found in

review, we share the proceedings of the meeting and discuss how

50% of all cases of NS, that individuals carrying PTPN11 mutations

these efforts further the groundbreaking discoveries, the clinical

are more likely to have pulmonary valve stenosis and less likely to

advancements, and the effective progress to treating these patients in

have hypertrophic cardiomyopathy (HCM), and that all de novo

the near future.

PTPN11 variants originate from the paternal copy in the presence of a
paternal age effect (Tartaglia et al., 2002; Tartaglia, Cordeddu,

2 | C EL E B R A T I N G T HE 2 0 T H
A N N I V E R S A R Y OF T H E D I S C O V E R Y O F
P T P N1 1 A S T H E F I R S T “ R A S O P A T H Y ” G E N E

et al., 2004). It was also discovered that the male-to-female ratio

Bruce Gelb, MD, and Marco Tartaglia, PhD, spoke on the history and

the pathogenic variants of NS were gain-of-function (GOF). Protein

discovery of PTPN11, the gene that encodes the Src homology

crystal structure analysis demonstrated that the majority of these vari-

2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2),

ants were indeed located at the interactive surface between the bind-

and identified as the primary cause of NS. Indeed, pathogenic variants

ing domains, rendering the protein catalytically active, and with an

in PTPN11 cause greater than 50% of all cases of NS, a finding that

increased binding affinity (Tartaglia, Niemeyer, et al., 2004, p. 2). This

paved the way for our understanding of RASopathies. Forty years

was experimentally confirmed by showing these mutations induced

prior, in 1962, Dr. Jacqueline Noonan was the first to describe a

increased phosphatase activity in vitro (Keilhack et al., 2005; Tartaglia

among these sporadic cases is 2:1. The absence of frameshift, nonsense, and splice-site mutations in PTPN11 also highly suggested that
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et al., 2006). In vivo, Benjamin Neel, PhD and his group created a

Furthermore, pathogenic variants can variably perturb intracellular sig-

mouse model of an NS-causing PTPN11 GOF mutation (Araki

naling, both qualitatively and quantitatively. Importantly, the discovery

et al., 2004) and found that the Ptpn11 protein product, SHP2,

of PTPN11 in NS paved the way to the discovery of the other

increased the risk of JMML (Mohi et al., 2005) and caused abnormal

RASopathy genes in the pathway and to the birth of “RASopathies” as

cardiac valvulogenesis (Araki et al., 2009).

a field of research and investigation. The next steps for researchers

In contrast to GOF NS variants, Drs. Gelb and Tartaglia, along

in the coming years include better understanding of the pathophysi-

with Drs. Neel and Maria Kontaridis, PhD, demonstrated that patho-

ology associated with dysregulated SHP2 activity and function and

genic variants causal to the allelic disorder NSML, formerly known as

greater insights on the dynamics associated with, and the extent to

LEOPARD syndrome, were loss-of-function (LOF) and had impaired

which, SHP2 signaling is dysregulated in the context of its cellular

catalytic activity (Kontaridis et al., 2006; Tartaglia et al., 2006).

milieu.

Y279C

Dr. Kontaridis's group further developed a knock-in Ptpn11

mouse model of NSML, which recapitulated nearly all of the features

3

associated with NSML in patients, including the HCM phenotype

AND OUR VOICE AS ADVOCATES

(Marin et al., 2011). Interestingly, they found that the mechanism of

Ms. Elisabeth Parker, a RASNet board member, is the mom of Judah

|

ADVOCATE KEYNOTE: FINDING A DIAGNOSIS

these NSML-associated PTPN11 mutations mediated increased

and of Ezra, who has NS. She is an advocate who is passionate about

AKT/mTOR signaling instead of increased Ras/MAPK signaling (Marin

creative fundraising, volunteering, speaking, and teaching yoga at

et al., 2011), a finding previously postulated by Dr. Raynal and col-

RASopathies and Rare Disease events. At the meeting, she shared

leagues based on in vitro data (Edouard et al., 2010; Hanna

that when asked what 8-year-old Ezra wants people to know about

et al., 2006). Using the mTOR inhibitor (mTORi) rapamycin,

NS, he responded, “Number one, I want people to know that when I

Dr. Kontaridis' group showed that they could both prevent and

was little, I had a tube in my belly, and number two, I had quinoa

reverse HCM in their mouse model. This led to the idea that rapalogs

[chemo, sic], that I had blood draws, that I had surgeries, and that I got

may be effective in treating patients with NSML. In this regard, a

sick a lot.” Because Ezra did not have the typical cardiac features of

patient with the NSML-associated PTPN11 variant Q510E, who pres-

NS, the path to his diagnosis was a long one. Ezra had early problems

ented with severe HCM and significantly increased AKT/mTOR activ-

with low blood sugar, feeding, and unexplained elevated blood count.

ity, was treated with everolimus for 12 weeks; in that time, the infant

Eventually, he was diagnosed with JMML. Etched into Ms. Parker's

showed significant improvement in heart function, stabilizing him

memory is a comment from one of his care providers soon after Ezra's

enough to receive a subsequent heart transplant (Hahn et al., 2015).

birth, “I've never seen a baby that looks like this.”. Experiences like

Dr. Gelb also studied the neurological implications of PTPN11 var-

this during her journey with Ezra and a firm belief that medical pro-

iants in a Drosophila model; his group demonstrated that memory

viders can and should communicate empathetically have made her the

impairments could be improved with alterations in conditioning proto-

passionate advocate that she is today. Moreover, although physically

cols (Pagani et al., 2009). In addition, Alcino Silva, PhD, using

small, Ezra's outsized personality continues to be inspirational. Armed

Dr. Neel's Ptpn11D16G GOF NS mouse model, showed that abnormali-

with this, Ms. Parker actively participates in Rare Disease Day on Cap-

ties in neurobehavior could be improved by treatment with lovastatin

itol Hill and in global Rare Disease events, has served as a board mem-

(Lee et al., 2014).

ber of the RASopathies Network, organizes fundraising yoga class

Dr. Gelb also showed that one could also utilize PTPN11-mutant
NSML inducible pluripotent stem cell (iPSC)-derived cardiomyocytes

events, and uses social media to promote ways to support parent
advocates' physical and mental health.

to recapitulate hypertrophy, the first to be used to model of a human
cardiovascular disease (Carvajal-Vergara et al., 2010). In addition, his

Session 1: Genes, pathways, and Genocopies

group showed that PTPN11-mutant JMML iPSCs could recapitulate

Moderated by Katherine Rauen, MD, PhD, the session started with

myeloid abnormalities with cell autonomous effects (Mulero-Navarro

Martin Zenker, MD, reporting on new gene candidates for the

et al., 2015).

RASopathies. RASA2 and YWHAZ are negative regulators of Ras and

Over the last 10 years, there have been significant efforts to tar-

Raf, but their precise clinical impact on the Ras/MAPK pathway needs

get SHP2 function and activity. However, direct inhibition of SHP2’s

further confirmation. CDC42 and RALA are components of a non-

catalytic activity has not proven clinically successful. An alternate

canonical Ras pathway, but neither functional nor clinical data have

approach, however, using an allosteric peptide molecule targeting the

yet sufficiently classified them as RASopathy genes (Schnabel

binding of SHP2 to its signaling partners may prove to be more effica-

et al., 2021). FBXW11 and TRAF7 have an uncertain link to the

cious (Bobone et al., 2021; Fodor et al., 2018; Garcia Fortanet

Ras/MAPK pathway. Hence, Noonan-like features in some mutation

et al., 2016). Another promising approach aims to inhibit SHP2 bind-

carriers may be a phenocopy.

ing partners and regulators, rather than SHP2 itself, as a way to modulate multiple SHP2-dependent outputs (Yi et al., 2016).

Dr. Tartaglia discussed the molecular genetics of RASopathies
along with common themes and novel mechanisms in Ras signaling

In summary, the body of work these last 20 years on SHP2 has

dysregulation. The majority of RASopathy syndrome genes have been

shown that PTPN11 pathogenic variants cause diverse human disor-

identified by using a hypothesis-driven approach based on gene can-

ders and can drive events that lead to pediatric malignancies.

didacy. The collection of data on the molecular spectrum of mutations

5
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for each of these genes has contributed to the appreciation of the dif-

HUWE1, the AAA+ ATPase proteins PSMC5 and VCP/p97, and the

ferential impact of RASopathy-causing and cancer-associated muta-

de-ubiquitinating enzyme USP7, to regulate MAPK pathway activity.

tions on protein function and intracellular signaling. He also presented

USP7 plays a central role in the regulation of this complex, by promot-

published and unpublished findings on the identification of MAPK1

ing the inactivation of MAPK signaling. SHOC2 mutations, which have

mutations as a new event underlying a novel RASopathy and on the

been described in individuals with NSLAH, disrupt the interaction with

identification of a second form of recessive NS resulting from biallelic

USP7, resulting in enhanced MAPK signaling (Wilson et al., 2021).

LOF variants in SPRED2 (Motta et al., 2020, 2021).

Caitlin Chang, MD, presented a series of clinical cases of patients

Yoko Aoki, MD, PhD, reviewed noncanonical GTPases RRAS2,

that had been diagnosed with mosaic RASopathies driven by KRAS

RRAS, MRAS, and RIT1 in which pathogenic variants in these genes

mutations. Somatic mosaicism occurs during embryonic development

were identified in individuals with an NS phenotype. Overall, there

and affects specific tissue lineages depending on when and where the

are more than 30 GTPases in the Ras subfamily. RRAS, RRAS2, MRAS,

driver mutation occurs. Dr. Chang described eight patients with KRAS

and RIT1 share 48%, 55%, 57%, and 44% sequence identity with

mutant mosaicism and their clinical features, which in several cases

HRAS, respectively, and have an N- or C-terminal extension. The

included embryonal tumors (rhabdomyosarcoma and Wilms tumor)

sequence identity of the effector domain is very high, but hypervari-

and other less common symptoms, such as epilepsy, polycystic kid-

able regions are unique and are predicted to have different lipid

neys, T-cell deficiency, and multifocal lytic bone lesions. In addition,

modifications.

the clinical experience from a patient treated with off-label MEK

Dr. Gelb presented a study on RASopathy genetic variation in

inhibitor (MEKi) was discussed (Chang et al., 2021).

biobanks. Rates of persons harboring a RASopathy variant in BioMe
and UKBB were 1:2300 and 1:2700, respectively. Few were diag-

Session 3: Lymphatic and cardiovascular manifestations

nosed with RASopathy, but a substantial fraction of individuals har-

David Stevenson, MD, and Sahar Mansour, MD, moderated a session

boring pathogenic or likely pathogenic variants exhibited partial or full

on lymphatic problems and lymphedema in RASopathies. Kristiana

phenotypic matches to these traits (Wenger et al., 2021). Overall,

Gordon, MD, discussed how pathogenic variants in RASopathy genes

there was a lower rate of RASopathy cardinal features in these indi-

mediate onset of primary lymphedema, a swelling of the peripheries

viduals than expected.

caused by an underlying weakness in the lymphatic system. Although
the weakness is probably present at birth, the swelling may not pre-

Session 2: Novel strategies and mechanisms in RASopathies

sent until childhood, adolescence, or adulthood, manifesting in lymph-

Pau Castel, PhD, and Annette Bakker, PhD, moderated a session that

edema of the legs and genital area. Patients can present with leaking

included talks related to novel therapeutic strategies and mechanisms

from the scrotum (chylous reflux) and can develop ascites,

of pathogenesis in RASopathies. Lukas Cyganek, PhD, reported on the

chylothoraces, or chylous pericardial effusions. Intranodal lymphangi-

generation of cardiomyocytes as cellular models derived from iPSCs

ography has also shown abnormalities of the central conducting lym-

from NS patients. The iPSC technology is extremely useful in the

phatic system, with excessive and tortuous lymphatic vessels. The

study of RASopathies, because it allows the generation of any cellular

Ras/MAPK pathway has an important role in lymphangiogenesis, so it

lineage from peripheral blood mononuclear cells (PBMCs) isolated

is not surprising that disorders in genes that reside along this pathway

from blood or from fibroblasts isolated from skin biopsies. In his talk,

affect this pathology. Indeed, it may be that up to 50% of RASopathy

Dr. Cyganek focused on iPSC-derived cardiomyocytes from a family

patients have lymphatic problems. Here, Dr. Gordon presented clinical

with NS caused by intronic mutations in the LZTR1 gene and showed

data from the primary lymphedema clinic at St. George's Hospital,

how these cells exhibit a hypertrophic phenotype that can be restored

London, where she has seen over 20 cases of lymphatic disorders in

by CRISPR/Cas9-mediated genome editing (Hanses et al., 2020).

patients with RASopathy. Specifically, she discussed three cases of

Dr. Kontaridis described a novel pharmacological approach for

individuals with a RASopathy who also presented with a central con-

treating NS-associated HCM with the small molecule rigosertib, a Ras

ducting lymphatic anomaly (CCLA). The first had a pathogenic variant

mimetic that inhibits both the MAPK and PI3K pathways. Using an NS

in BRAF. He presented at 28 years old with lower limb lymphedema

knock-in mouse model with the Raf1L613V mutation, Dr. Kontaridis

and chylothoraces, which failed to resolve despite several different

showed that a 3-week treatment schedule with rigosertib normalized

therapeutic measures (e.g., thoracic duct ligation, pleurodesis,

chamber dimensions, posterior wall thicknesses, heart weight, and car-

sirolimus, and octreotide). The patient responded for some time to

diomyocyte size in female mice. Results in male mice looked promis-

high doses of diuretics, but sadly died following a seizure. The second

ing, but as yet were inconclusive. These preclinical results support the

patient is 24 years old with a de novo pathogenic variant in RIT1. He

development of rigosertib for the treatment of RAF1-associated

has bilateral lower limb lymphedema with severe genital swelling and

hypertrophic cardiomyopathy in patients.

chylous reflux. He developed marked ascites, chylothoraces, and chy-

Emilia Galperin, PhD, presented data from her laboratory regard-

lous pericardial effusions, which required surgical drainage. He had

ing the mechanism of the scaffolding protein SHOC2 in the regulation

multiple hospital admissions and did not respond to the usual modes

of the MAPK pathway. Dr. Galperin showed that SHOC2 orchestrates

of management. He was started on a MEKi, trametinib. The ascites

a molecular complex formed by the E3 ubiquitin ligase protein

resolved within a few weeks and the pericardial effusion improved

6
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over a few months. However, the genital edema continued. He has

The results suggest that dasatinib may be a potential therapeutic

not had a hospital admission since starting the MEKi and is back in

agent for HCM in NSML patients (Yi et al., 2021).

employment. The third case is a 10-year-old boy with a de novo pathogenic variant in RIT1. He has had chylothoraces in the past, treated
to some degree with bilateral pleurodesis. He is currently stable, but

4

his intranodal lymphangiography demonstrates a marked CCLA. The

Moderated by Beth Stronach, PhD, the scientific keynote presenta-

difficulty is knowing whether or not, and if so when, to start him on a

tion by Gregor Andelfinger, MD, focused on the role of MEK and

MEKi, as there is concern his condition may continue to deteriorate.

mTOR inhibition in RASopathy-associated cardiac disease. HCM is

|
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Maxim Itkin, MD, next discussed the patterns and therapeutic

evident in 10–20% of patients with a RASopathy and treatment

options in Noonan syndrome-related lymphatic disorders. As dis-

options remain very limited. Infants <6 months old with RASopathy-

cussed above, patients with a RASopathy, in this case NS, often pre-

associated HCM can develop congestive heart failure, leading to poor

sent with clinical signs of lymphatic disorders. Recent developments

survival. They face heart transplantation as the only viable option for

in lymphatic imaging techniques, such as dynamic contrast enhanced

primary treatment. The pathophysiological mechanism of RASopathy-

MR lymphangiography and intranodal lymphangiography, allow for

associated HCM is thought to be due to elevated Ras signaling,

new insights into the anatomy and pathophysiology of the lymphatic

suggesting a potential benefit from Ras pathway inhibition. Indeed,

system. One of the main findings in almost all patients with NS is the

elevated Ras signaling through the PI3K/AKT pathway in NSML or

increase in lymphatic flow rate. This can be explained by patients hav-

the Raf/MEK/ERK pathway in NS provides the rationale for consider-

ing either an increase in permeability of the capillaries or having a

ing compassionate use of mTORi or MEKi therapy, respectively

venous insufficiency and/or venous obstruction. The increase in the

(Marin et al., 2011; Wu et al., 2011). Before embarking on compas-

lymphatic flow rate results in lymphangiectasia, which in turn causes

sionate use treatment for direly sick patients, it is essential to

lymphatic valve insufficiency and lymphatic reflux. The clinical presen-

thoughtfully consider the appropriate therapeutic window, drug dos-

tations of lymphatic reflux include chylothorax, chylous ascites, pro-

age, treatment duration, outcome measures, access to, and cost of

tein losing enteropathy, and genital lymphorrhea. Novel treatment

drug treatment. Comparing the strength of ERK signaling—baseline,

approaches include interstitial/mesenteric lymphatic embolization,

elevated, or excessive in unaffected, RASopathy, or oncology con-

and percutaneous and/or surgical thoracic duct decompression, all of

texts, respectively—informs the choice of MEKi dosing, with the aim

which provide successful treatment options for these conditions. All

to normalize signaling using a low or moderate dose of inhibitor over

patients presenting with clinical symptoms of lymphatic disorders

an extended time course, rather than to terminate signaling (and can-

should undergo lymphatic imaging to determine possible treatment.

cer) with an acute high dose therapy. Starting in 2014, compassionate

Systematic imaging studies of the lymphatic system in NS could help

use of MEKi or mTORi for progressive RAS-HCM began to be consid-

to further understand the effects of the changes in the lymphatic sys-

ered. By 2018, at least three patients had been treated in pilot first-

tem on the health of patients with a RASopathy (Othman et al., 2021).

use cases (Andelfinger et al., 2019; Hahn et al., 2015; Nelson, 2019).

Anton Bennett, PhD, presented on novel therapeutic strategies

Increasing use over the last 2 years in more than two dozen individ-

for the treatment of HCM in NSML. Up to 85% of NSML cases are

uals from 17 institutions on two continents has culminated in a case

caused by pathogenic variants in PTPN11. Utilizing the NSML

cohort series (for forthcoming publication), paving the way for phased

Y279C/+

Ptpn11

knock-in mouse model created by the Kontaridis labo-

trial development considerations. Dr. Andelfinger reported evidence

ratory, which develops HCM by 12 weeks of age, Dr. Bennett and his

from the treatment of this cohort, which showed improved measures

group found that a transmembrane SHP2 binding protein called

of heart function and overall survival, significant avoidance of surgery,

protein-zero related (PZR) is increased in its level of phosphorylation

and moderate prevalence (50%) of mostly manageable adverse

and binding in the hearts of these mice. When a mutation of PZR that

effects primarily on the gastrointestinal tract and skin/hair. The posi-

blocks SHP2 binding is introduced into the NSML mice, HCM is

tive effects of small molecule inhibitors in these RASopathy cases

blocked and AKT activity is normalized, suggesting that the interaction

have excited the community, yet successful weaning from inhibitor

between PZR and SHP2 drives NSML-associated HCM. Using

treatment will require continued surveillance to monitor response

dasatinib (Sprycel), an FDA approved drug for the treatment of

durability and relapse. To conclude his presentation, Dr. Andelfinger

chronic myeloid leukemia in adults and acute lymphoblastic anemia in

recounted this cohort's experience, namely that low dose trametinib is

children, Dr. Bennett showed that he could block the interaction

safe and effective; it provides functional and survival benefits to

between PZR and SHP2 and inhibit PZR tyrosyl phosphorylation in

patients; regression of phenotypes is seen in patients with different

the NSML mice, even at a dose up to 100-fold lower than that used

causal RASopathy genes/variants; and that any adverse effects must

to treat cancer patients. He further validated low toxicity and low

be managed with continued monitoring.

lethality with this treatment. Importantly, echocardiograms on the
mice proved that low dose dasatinib, when used before 12 weeks,

5

could prevent the development of HCM and reduce fibrosis in the

Moderated by Dr. Stronach and Lisa Schill, BS, a diverse group of fam-

heart. He also gave the drug at 14 weeks of age, after the presenta-

ilies shared oral stories accompanied by photos of their experiences

tion of HCM, which reversed the hypertrophy in the cardiac muscle.

living with a RASopathy as part of this year's virtual format. The

|
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session included individual presentations by five parents of children

seizures among study participants was provided based on information

with RASopathy: one with CFCS, one with CS, one with NF1, two

obtained from review of medical records and caregiver-completed

with NS, and one young adult self-advocate with NS. Each family rep-

electronic surveys. Dr. Pierpont discussed genotype–phenotype asso-

resented a different causal gene variant. The purpose of the session

ciations with respect to seizures and neurodevelopmental outcomes.

was to uncover disease impact on families, understand the patient

Relationships between adaptive skills of study patients and the sever-

and caregiver experience, and appreciate the humanistic side of

ity of seizure burden, as well as the genotype correlation, were also

patients and families in their natural environments. Advocates dis-

examined. Her conclusion emphasized that molecular genetic testing

cussed both the successes and challenges in their families' journeys—

can aid in the prediction of epilepsy in CFCS.

through diagnosis, specialist care needs, growing awareness and benefits

of

advocacy,

reaching

milestones

and

often

exceeding

expectations.

Domenica Battaglia, MD, focused on BRAF mutations in CFCS
and described the electro-clinical features, natural history of disease,
long-term outcomes, and responses to therapy. Data were longitudi-

One parent described her child's clinical and genetic diagnosis;

nal and collected from 34 patients (11 males, mean age of

her son had a very rare variant in YWHAZ, a new gene associated with

15.8 ± 10.6 years, mean follow-up of 9.2 ± 4.7 years). Of the patients,

CFCS. She appealed to researchers to learn more about the function

64% (22) presented with epilepsy; 10 individuals with severe develop-

of this gene, before it is too late for her son. Another parent described

mental and epileptic encephalopathy; and 12 had a mild epileptic phe-

her child's experience taking an experimental MEKi off-label, and how

notype. EEG characteristics of these two groups were described. A

the treatment has helped improve her child's heart condition, stabiliz-

genotype–phenotype correlation linking the presence and severity of

ing HCM and resolving PVS, ultimately avoiding the imminent need

epilepsy to the nature of the structural and functional consequences

for heart transplantation. Each story touched on a particular need or

of mutations was documented. Specifically, the amino acid substitu-

wish based on the family's experiences, mentioning, for example, the

tions affecting residues located within or close to the active site of

need for vision screening; for awareness of bleeding and constipation

the kinase were associated with a more severe epileptic phenotype,

issues; the hope for improved tumor diagnosis and earlier intervention

while those affecting residues placed close to the regulatory 14-3-3

on tumor growth; fewer side effects from current available treat-

protein binding surface were associated with mild or no epileptic phe-

ments; better care coordination; and educational and emotional sup-

notype. These data provide a stratification based on genotype to

port. Families also emphasized the importance of community,

improve the clinical management of these patients (Battaglia

connecting with other families to obtain perspective, learn more, sup-

et al., 2021).

port each other, and to share in their experiences. Gaining an under-

Closing out this session, Shruti Garg, MBBS, MRCPsych PhD,

standing of the perspectives, unique needs, and challenges of a

described the social behavioral phenotype in the RASopathies, focusing

diverse group of patients and their families living with RASopathies

on NF1, NS, and CFCS. She provided published evidence to show how

will help researchers and clinicians enhance future treatments and

the Ras/MAPK pathway may be affected in non-syndromic autism spec-

care in the RASopathies, with the ultimate goal of improving the over-

trum disorder (ASD) (Geoffray, Falissard, et al., 2021). For example, 10–

all quality of life.

25% of children with NF1 present with ASD and up to 40% of them have
social impairment. In research published by her group, in a cohort of chil-

Session 4: Neurocognitive associations

dren with NS (n = 40, 25 males), 30% met the research criteria for ASD

Marni Axelrad, PhD, and Tamar Green, MD, moderated a session on

and another 30% had partial ASD symptoms, as assessed by the ASD

neurocognitive associations in RASopathies. This session focused on

gold standard measures (Geoffray, Robinson, et al., 2021). The male-to-

data collected from individuals with a RASopathy and information

female ratio of ASD in NS is 1:5. Additionally, 52% of children with NS

about the brain manifestations, including data regarding brain tumors,

have comorbidity with ADHD. Notably, ASD symptoms are not corre-

seizures, and neurodevelopmental issues such as autism spectrum dis-

lated with IQ or ADHD diagnosis. Comparing ASD symptoms across the

order (ASD). Alberto Broniscer, MD, reported preliminary results of a

Ras/MAPK disorders, including NS, NF1, and CFCS, children with CFCS

multi-institutional study addressing the association of CNS cancers

showed the most significant delay in developmental milestones, com-

with non-NF1 RASopathies. The majority of subjects in this study had

pared to the other cohorts. However, the ASD behavioral profile is similar

NS and were younger than 18 years of age. The most commonly

across all RASopathy groups. Interestingly, the NF1 group showed higher

found cancers were low-grade gliomas, which usually had an indolent

levels of social communication difficulties and lower levels of restrictive

behavior. Based on the study design, however, no conclusions could

repetitive behaviors, compared to NS and CFCS groups. Dr. Garg

be drawn regarding the incidence of CNS cancers in this population.

suggested there could be an issue of diagnostic overshadowing, where

Additionally, no systematic screening for CNS cancers is currently rec-

social impairments can often be attributed to ADHD and intellectual

ommended for children with NS.

impairments, without a thorough assessment of ASD symptoms.

Rene Pierpont, PhD, shared preliminary findings of her multicenter investigation of neurological and neurodevelopmental features of

Session 5: Understudied clinical manifestations of RASopathies

CFCS. Study enrollment included 138 individuals with molecularly

Common manifestations of RASopathies include short stature, cranio-

confirmed diagnosis. An overview of the semiology and severity of

facial features, and congenital heart defects. In this session moderated
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by Jeroen den Hertog, PhD, understudied manifestations of

postnatal administration of MEKi can rescue aspects of the abnormal

RASopathies were addressed. Karen Gripp, MD, discussed CS-

muscle phenotype in CFCS.

associated tumor formation. Tumors may arise in syndromic back-

Maija Kiuru, MD, PhD, discussed skin and hair manifestations that

grounds, as well as in individuals with mosaic CS. The majority of

are important in making clinical diagnoses of RASopathies. There is

reported CS syndromic cases have variants in HRAS residues 12 and

significant overlap in these features between patients with CFCS and

13, and a minority of cases have variants in other residues. All syn-

CS, including curly hair and thickening of the palms and soles. How-

dromic cases reported to date that develop embryonal rhabdomyosar-

ever, there are also clear differences. For instance, absent or sparse

comas have specific mutations in residue 12, including G12S, G12C,

eyebrows, darker and thicker scalp hair, and keratin-clogged hair folli-

and G12A. Moreover, all of these variants are paternally derived and

cles and sweat ducts are typically only observed in CFCS (Urban

display uniparental disomy (UPD) for chromosome 11, which carries

et al., 2020). Conversely, papillomas on the nose and face and deep

the HRAS gene. HRAS mutations are commonly found in isolated can-

acral creases are more typical in CS. There is also an overlap in genes

cers, with hotspots identified at residues 12, 13, and 61 in the COS-

associated with melanoma and the RASopathies, in that mutations in

MIC database (Tate et al., 2019). Yet, it is notable that the G61 variant

BRAF, NRAS, and NF1 in melanoma are also well-known RASopathy-

is not typically seen in CS. Several mosaic CS cases were discussed;

associated genes. In patients with CFCS, a significant increase in the

some showed typical CS features but harbored typical CS variants

number of melanocytic nevi is observed (Kiuru et al., 2020). Impor-

only in a small subset of cells and tissues. For example, the mother of

tantly, while the number of nevi is usually the strongest risk marker of

a child with CS was found to have mosaicism for a typical CS variant,

melanoma, this association for CFCS remains as yet unknown. How-

providing evidence for maternally derived CS. Several other mosaic

ever, protection from UV light—another risk factor in melanoma—and

HRAS variants with G12S mutations identified in various tumor types

regular skin exams are recommended for these patients.

were also described, including cases of urothelial cell cancer and blad-

Suma Shankar, MD, PhD, presented an overview of ocular mani-

der cancer. Moreover, a mosaic HRAS variant with G13R mutation—

festations in RASopathies based on retrospective medical record anal-

which has not been reported previously in CS, but has been found in

ysis and cross-sectional studies, particularly as it pertains to patients

tumors—was associated with two independent embryonal rhabdo-

with CFCS, CS, and NS (Gripp et al., 2019; Pierpont et al., 2014). Eye

myosarcomas. In conclusion, if the HRAS mutation is present from

manifestations are present in more than 90% of individuals with a

fertilization onwards, tumor incidence depends on the specific muta-

RASopathy, with the most common symptoms including blurred

tion. However, if the HRAS mutation occurs post-zygotically, tumor

vision, problems with stereopsis, and photophobia. Upon exam and

incidence depends on the specific mutation and on the affected

chart review, a majority of these individuals also had strabismus,

tissue.

refractive errors, nystagmus, ptosis, and optic nerve anomalies, find-

Katherine A. Rauen, MD, PhD, addressed skeletal muscle hypoto-

ings that are much more common in individuals with a RASopathy

nia in patients with CFCS, which manifests in the newborn period

than in the general population (p < 2.2E-16). Rarely, additional fea-

with delayed motor skills, muscle weakness, decreased muscle bulk,

tures, including keratoconus, prominent corneal nerves, retinal dystro-

and suck-swallow issues. Muscle weakness appears to improve some-

phies, delayed visual maturation, and cortical visual impairment, were

what when children grow older, but muscle bulk typically stays under-

noted. Ocular features such as refractive errors, strabismus, nystag-

developed, and some children are not ambulatory. To investigate

mus, and ptosis may present in infancy or later, and are amenable to

L597V

these manifestations, a mouse model for CFCS carrying a Braf

correction with glasses and/or surgery (Shankar et al., 2021). Conse-

mutation was used (Andreadi et al., 2012). These mice have decreased

quently, pediatric ophthalmology evaluation at the time of diagnosis,

skeletal muscle mass and decreased muscle strength (Maeda

with routine biannual or annual follow-up, is recommended to prevent

et al., 2021). While no apparent differences in morphology were

amblyopia, facilitate optimal vision development, improve vision, and

observed, the muscle fibers were found to be significantly shorter in

improve the quality of life for these individuals.

BrafL597V mice than in wild type mice. Whole mount immunohistochemistry of mouse embryos at E11.5 showed reduced staining using

Session 6: Selected junior investigator presentations

a myogenin-specific probe, indicating inhibition of myogenesis in the

Tirtha Das, PhD, presented multiple Drosophila models that identify

mutant mice. Analysis of signaling demonstrated enhanced MEK and

RASopathy subtype-specific differences. The Drosophila model has

ERK phosphorylation and downregulation of p38 phosphorylation.

been a powerful genetic system with which to decipher fundamental

Primary myoblasts were derived from wild type and BrafL597V mouse

cell and developmental biology questions, and it includes discovery of

embryos; in vitro differentiation of these myoblasts was impaired in

components of the Ras/MAPK pathway. To gain a more comprehen-

mutant cells, as compared to wild type. Treatment with a MEKi res-

sive understanding of how variants in genes encoding Ras/MAPK

cued differentiation of mutant myoblasts. Just as important, under

components are associated with RASopathies, he developed 13 Dro-

these conditions, the MEKi did not significantly impact differentiation

sophila transgenic lines. Each fly line expressed a different human dis-

of wild type myoblasts. Taken together, the BrafL597V mouse model

ease isoform associated with a RASopathy. Using these models, he

for CFCS develops skeletal myopathy and may be instrumental in

developed a platform that explored tissue phenotypes, signaling path-

determining the feasibility of developmentally correcting this myopa-

way activity, changes in cell biology, deregulation of transcriptional

thy by prenatal administration of MEKi. Moreover, it is possible that

targets of signaling pathways, and response to potential therapeutics
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(Das et al., 2021). In addition, the group performed targeted genetic

Session 7: Learning from each other: Perspectives on diagnostics and

modifier tests to gain insights into mechanisms promoting disease

therapeutic interventions

progression, as well as to validate or identify novel targets for thera-

Stephanie Ware, MD, PJ Brooks, PhD, Bruce Korf, MD, PhD, and Jeff

peutics. Specifically, they discussed how expressing the RAF1L613V

R. Livingstone, PhD, held a roundtable discussion moderated by Stas

variant in developing wing tissue promoted excess wing vein forma-

Shvartsman, PhD, to discuss therapeutic interventions in the

tion, suggesting a GOF effect of this variant. In contrast, similar

RASopathies. Dr. Ware highlighted the need for early diagnosis of

variant inhibited wing vein forma-

patients with a RASopathy. Currently there is no “standard of care” to

tion, suggesting a potential dominant negative effect of this mutation.

determine if a genetic evaluation should be triggered for babies enter-

A multi-panel western blot analysis of these two variants showed that

ing the newborn intensive care unit. She also discussed the need for a

both could activate markers of multiple signaling pathways. Using the

more tailored approach for use of repurposed treatments in

D486G

newly developed CRIMIC technology, they found that the RAF1

RASopathies. Many questions remain regarding treatment consider-

variant rescued a small percentage of flies (2–5%), allowing them to

ations, including type and extent of treatment for the different

reach adult stages, even in the absence of endogenous Raf function.

RASopathy syndromes and if there is a critical window in which to do

Taken together, the group postulated that RAF1D486G, previously

so. A national registry for patients on treatment regimens that outlines

described as a LOF variant, had a more complex function than previ-

their experiences would be extremely useful.

D486G

expression levels of the RAF1

ously known. Indeed, this RAF1D486G variant could directly or indi-

Dr. Korf discussed the need to explore both shorter term thera-

rectly activate Ras/MAPK (and other signaling pathways), and thereby

peutic options, such as small molecule treatments, as well as longer

rescue loss of Ras/MAPK function. Conversely, in other contexts, the

term options, such as gene replacement or genome editing in the

same variant can also have dominant negative effects on the same

RASopathies. There was also agreement on the need for a concerted

pathway (e.g., wing). In the future, using additional Drosophila lines

effort to bring the natural history data of the RASopathies together in

(33 in total), the group plans to provide a broad overview of how

a centralized database.

RASopathy variants alter the signaling network in different tissues.

Dr. Livingstone, CEO of Igia Pharmaceuticals, discussed the diffi-

These data may provide valuable insights into how pathogenic vari-

culty in approvals and the increased costs associated with repurposing

ants promote specific traits in humans, as well as enable tailored ther-

small molecule treatments for rare diseases, in large part due to the

apeutic approaches to treat them.

small population size and the regulatory hurdles needed to do

 pez-Juárez, PhD, discussed how abnormal myelin difAlejandro Lo

so. However, the RASopathies have an advantage—multiple syn-

ferentially impairs learning in models of NF1 and CS. He showed that

dromes can be treated by targeting a single pathway. He also dis-

adult Nf1+/ mice have increased oligodendrocyte (brain myelin pro-

cussed the importance of leveraging patient advocacy groups and the

ducing cells) precursor cells with less proliferative capacity. Nf1+/ mice

need for more interaction with these groups.

also showed late subnormal learning when subjected to a myelin-

Dr. Brooks, from the National Center for Translational Science

regulated fine motor skill test (running on a Complex Wheel; CW). Such

(NCATS), discussed the role of the NIH and NCATS in supporting

defects were attributed to a progressive loss of activity, without

basic science. He provided information on NCATS funding (https://

affecting capability to run. Similar results were observed in mice with

ncats.nih.gov/funding/open) and mentioned that basket clinical trials

myelin-specific Nf1 mutation, supporting the idea of a myelin-regulated

to determine the effects of treatments on multiple diseases at the

phenotype. In contrast, mice with a myelin-specific CS-causing mutation

same time may be applicable to the RASopathies.

showed early abnormalities in the CW learning curve, but these were

In summary, the panel viewed the importance of community

caused by decreases in the maximum speed achieved. In connection

efforts, including access to diagnostic testing, patient registries, defini-

with previous findings on RASopathy-associated myelin structural

tion of endpoints in clinical trials, and collaborative clinical trials, as

defects, it was suggested that parameters controlling learning in NF1

critical to achieving success in developing and testing treatments for

and CS are differentially regulated by myelin integrity and/or plasticity.

RASopathies. Patient advocacy groups were also viewed as crucial

Richard Van, BS, and Morgan Wagner, BS, presented a biochemical analysis of RIT1, which revealed preferential interaction at the

partners in all these efforts, facilitating and guiding the science to
finding successful therapies for patients.

plasma membrane with RAF1 and provided evidence for therapeutic

The symposium closed with a family panel discussion on the com-

intervention of cardiac hypertrophy. Indeed, RIT1 uses a combination

passionate use of MEKi for treatment of RASopathies, which was

of specific hydrophobic residues and electrostatic interactions in its

moderated by Pilar Magoulas, MS, CGC, and Ms. Schill. This panel

polybasic regions to associate with the plasma membrane. Interest-

included parents of individuals with different RASopathies who have

ingly, RIT1 shows preferential binding to RAF1 compared to ARAF

tried MEKi for different indications. Each of the panelists were asked

and BRAF, which may help to explain the high incidence (54%) of

questions regarding the decision to undergo treatment with MEKi, the

HCM in RIT1-associated NS. In a preclinical trial using a Rit1 mouse

perceived benefits and limitations, as well as the impact of the MEKi

model of NS (Castel et al., 2019), treatment with trametinib prevented

on their child's symptoms.

progression of cardiac hypertrophy, as determined by heart weight

The first panelist was a father of an 8-year-old boy with NF1 who

and myocyte size. This study provides more evidence for the use of

had a large plexiform neurofibroma. The family had previously tried to

trametinib in children with NS and RIT1-associated HCM.

get enrolled in a phase 3 clinical trial for a MEKi, but was unsuccessful.
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Their oncologist, however, was able to prescribe trametinib off-label

in their opinion, they felt that the benefits for their children, given

through an expanded use for the treatment of plexiform neurofi-

their medical complications, far outweighed the risks. As more individ-

bromas. The child was on trametinib for approximately 2 years before

uals with RASopathy receive MEKi on a compassionate use basis, the

switching to selumetinib, when it received FDA approval. The father

anecdotal experience of the parents and patients themselves will be

expressed satisfaction with the use of the MEKi and commented that

crucial to understanding and ascertaining their use for future clinical

his son expressed less pain, tickling and tingling sensations, felt a dif-

trials. Indeed, we may find even more unexpected benefits to MEKi

ference in the texture and nature of the neurofibromas and plexiform

usage for the RASopathies, ones that may be even more critical and

neurofibromas, and that the plexiform neurofibroma itself had stabi-

important to the quality of life of these individuals.

lized in size over time.

In summary, results from current research efforts are finally making

The second group of panelists were parents of a 9-year-old girl

their way to the clinic for treatment of patients with a RASopathy. The

with CS who had severe HCM. She had two previous open heart sur-

progress that is being made will have a significant impact on the lives of

geries to remove accessory tissue on her mitral valve when, at

both the affected individual and their families. The seventh International

8½ years of age, the parents were told that the child would need

RASopathies Symposium highlighted the research knowledge we have

another surgery within the next 6–12 months for correction of her

gained over the years that has now allowed us to find potential life-

septal wall and aortic stenosis. It was at that time that the parents

changing and effective therapies. The hard-fought efforts of patients,

decided to try a MEKi for their child rather than go through a third

advocates, research scientists, clinicians, drug companies, and regulatory

open heart surgery. Their daughter has now been on a MEKi for the

agencies have finally moved the needle forward; indeed, the time for

last 9 months and doing very well. She has not had progression of her

treating RASopathies in the clinic has arrived.

heart disease and her echocardiograms have reportedly stabilized,
whereas in the past they had progressively worsened over time. Anec-
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